ST交昂(600530) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,912,619.04, a decrease of 9.24% compared to ¥178,398,351.17 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥11,731,826.35, down 42.56% from ¥20,424,555.96 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,990,071.24, a decrease of 26.40% compared to ¥16,289,819.66 in the same period last year[21]. - Basic earnings per share decreased by 42.15% to CNY 0.015 compared to the previous period[23]. - Diluted earnings per share also decreased by 42.15% to CNY 0.015[23]. - The weighted average return on equity dropped by 0.98 percentage points to 1.33%[23]. - The company reported a total of CNY -258,244.89 in non-recurring losses after tax adjustments[25]. - The net profit for the first half of 2022 was CNY 13,439,891.33, a decline of 41.9% compared to CNY 23,128,202.61 in the first half of 2021[104]. - The company reported a total comprehensive income of CNY 8,882,355.32, down from CNY 24,344,292.52 year-on-year[105]. Cash Flow and Assets - The net cash flow from operating activities increased by 6.18% to ¥41,495,647.66 from ¥39,080,452.35 in the previous year[21]. - The total assets at the end of the reporting period were ¥1,403,191,152.75, an increase of 3.76% from ¥1,352,345,202.99 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were ¥883,024,939.34, up 0.82% from ¥875,850,649.00 at the end of the previous year[21]. - The total cash and cash equivalents at the end of the period were 167,094,608.20 RMB, up from 86,402,028.05 RMB at the end of the first half of 2021[111]. - The total liabilities increased to CNY 480,739,699.81, compared to CNY 438,776,105.37 at the beginning of the period, reflecting an increase of 9.6%[96]. - The company's equity attributable to shareholders rose to CNY 883,024,939.34, up from CNY 875,850,649.00, marking an increase of 0.1%[96]. Business Operations - The main business includes the R&D, production, and sales of food and health food products, as well as the operation and management of elderly medical care institutions[26]. - The health food segment's production includes self-produced and outsourced products, with various product lines such as oral liquids and capsules[27]. - The sales model combines offline and online channels, with offline sales through major retailers and pharmacies, and online sales through TV shopping and e-commerce[28]. - The health food industry is expected to grow due to increasing disposable income and a rising willingness to pay for health products[28]. - The company anticipates that the demand for functional health foods will create greater market opportunities in the future[28]. - The company's medical care segment generated a total operating income of RMB 81.1 million, with a net profit attributable to the parent company of RMB 22.9 million during the reporting period[39]. - The total number of beds occupied at the end of June was 2,805, reflecting a year-on-year decrease of approximately 3.5% due to pandemic-related restrictions[39]. Risk Management - The company has detailed potential risks in the management discussion and analysis section of the report[7]. - The company faces risks from strict industry regulations, raw material price fluctuations, and reliance on medical insurance payments[50]. Corporate Governance - The company held two shareholder meetings during the reporting period, complying with legal regulations and ensuring valid resolutions[55]. - The board of directors underwent significant changes, with new appointments including Ji Lin as Chairman and Zhang Yunjian as President[56]. - The company has not reported any significant changes in its corporate governance structure beyond the recent board elections[57]. Environmental Responsibility - The company faced an administrative fine of 360,000 RMB due to environmental compliance issues related to wastewater treatment[61]. - The company is committed to environmental responsibility, conducting regular maintenance on wastewater systems to prevent leaks[62]. - The company implemented energy-saving measures in its boilers, achieving an annual reduction of approximately 195 tons of standard coal through improved heat recovery[63]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders is 34,819[79]. - The largest shareholder, Dazhong Transportation Group Co., Ltd., holds 14.38% of the shares, totaling 112,184,187 shares[81]. - Shanghai Yunjian Industrial Development Co., Ltd. holds 10.56% of the shares, totaling 82,362,600 shares[82]. - The company approved a share repurchase plan with a total amount not less than RMB 25 million and not exceeding RMB 50 million, with a maximum repurchase price of RMB 6.91 per share[84]. Research and Development - R&D expenses increased due to higher investment in research and development[42]. - The company has obtained 34 national patent authorizations, including 9 for probiotic inventions, showcasing its strong technological capabilities[31]. Financial Management - The company has established a cost control analysis system to monitor operational costs across various levels, enhancing its competitive advantage in cost management[36]. - The company has achieved a significant reduction in financial expenses by 75.97%, from RMB 8.9 million to RMB 2.1 million[40]. - The company reported a decrease in investment income due to the disposal of Suzhou Sanxiang Road Elderly Apartment in the previous period[42]. Compliance and Reporting - The report has not been audited, and the management has confirmed the accuracy and completeness of the financial report[5]. - The financial statements are prepared based on the enterprise accounting standards, reflecting the company's financial status and operating results accurately[136].